Octreotide
Indication
Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Red
Brand:
Sandostatin, Sandostatin LAR®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Immune system and Malignant Disease
Background
Octreotide are recommended for the non-acute treatment of recurrent gastrointestinal bleeding disorders. Initiation and continued supply of Octreotide is the responsibility of hospital or specialist services.
Octreotide are not licensed for this indication and there is not a large body of evidence to support this unlicensed use.
Treatment should only be continued if an adequate response is achieved (e.g. a 50% reduction in the need for transfusion or parenteral iron).
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: